The adoption argument is over. Roughly three quarters of US health systems now run at least one AI application, up from 59% a year earlier, and about 71% of non-federal acute-care hospitals have predictive AI wired into their EHR. The interesting question in 2026 budgets is different: industry surveys show the top spending priority has shifted from "find new use cases" to "make the AI we bought actually perform." That shift is worth respecting.
Average reported return on AI investment among healthcare organizations, typically realized within about 14 months, per 2026 industry survey aggregations. Averages hide variance; the returns cluster hard.
Administrative document flows. Referral intake, prior-authorization assembly, claims and denial paperwork, records requests. These processes run on faxes and PDFs, the labor is measurable, and nobody's license is on the line if a draft needs correction before a human sends it. This is where the venture money went too: the standout growth companies of the past two years automate paperwork, not diagnosis.
Revenue cycle. Denials run near 12% of claims nationally, most appeals succeed when actually filed, and every recovered claim is countable dollars. AI that drafts appeals and flags coding gaps pays for itself in recovered claims.
Internal knowledge and reporting. The unglamorous middle of every organization: regulatory reports assembled by hand, questions answered by whoever has been there longest. Retrieval-grounded assistants over your own documents, and pipelines that draft recurring reports, remove real hours with low risk.
Clinical documentation is real but contested. Ambient scribes are the most visible healthcare AI purchase, and clinicians largely like them. But published evaluations show uneven utilization and no automatic productivity gain, and the capability is rapidly becoming a bundled feature of the systems you already own rather than a product worth a separate line item. Buy it for clinician experience if you want it; don't book phantom FTE savings.
Anything sold as a platform. The cautionary tale of the last cycle was a four-billion-dollar automation vendor that shut down after customers discovered the ROI figures were estimates. The lesson isn't that AI fails. It's that "transformation" doesn't have an invoice you can audit. One workflow, one measured before-and-after, then the next workflow.
Before any AI line item survives your 2026 budget, it should answer three questions in one page. Which specific workflow, with what current cost in hours or dollars? What is the measured baseline today? Who checks the output before it acts, and what does that cost? If a vendor can't fill in that page, the pilot will drift. If your own team can't, that's a measurement problem, and measurement is cheaper to fix.
Sources: adoption and ROI figures aggregated in DemandSage's 2026 healthcare AI statistics and Azumo's 2026 review; budget-priority shift per MindInventory's 2026 global report; denial rates from national payer-claims analyses; scribe evaluation findings from published health-system cohort studies.